BCS Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

BCS Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Hold	12,083	–	–	0.04%	266
2026 Q1	$179K	Sell	12,083 -12,083	-50%	-$177K	0.04%	247
2025 Q4	$385K	Buy	24,166 +11,996	+99%	+$170K	0.04%	254
2025 Q3	$134K	Hold	12,170	–	–	0.03%	246
2025 Q2	$103K	Hold	12,170	–	–	0.02%	263
2025 Q1	$98K	Hold	12,170	–	–	0.03%	243
2024 Q4	$109K	Hold	12,170	–	–	0.03%	255
2024 Q3	$89K	Hold	12,170	–	–	0.04%	167
2024 Q2	$69K	Hold	12,170	–	–	0.03%	155
2024 Q1	$61K	Hold	12,170	–	–	0.02%	235
2023 Q4	$109K	Hold	12,170	–	–	0.04%	219
2023 Q3	$95K	Hold	12,170	–	–	0.04%	198
2023 Q2	$118K	Buy	+12,170	New	+$126K	0.09%	113
2023 Q1	–	Sell	-11,170	Closed	-$48K	–	163
2022 Q4	$48K	Buy	11,170 +1,000	+10%	+$5.8K	0.02%	189
2022 Q3	$76K	Buy	+10,170	New	+$88K	0.04%	176

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCS Wealth Management's AUPH Position: Q2 2026 in Review

BCS Wealth Management held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 12,083 shares worth $205K. The position accounts for 0.04% of the portfolio, ranked #266.

BCS Wealth Management first reported a position in AUPH in Q3 2022 and has held it in 15 quarters since. The position peaked at $385K in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

BCS Wealth Management held 12,083 shares of Aurinia Pharmaceuticals worth $205K as of Q2 2026.
BCS Wealth Management left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up 0.04% of BCS Wealth Management's portfolio in Q2 2026, its #266 holding.
BCS Wealth Management first reported a position in Aurinia Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
BCS Wealth Management's Aurinia Pharmaceuticals position peaked at $385K in Q4 2025.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on BCS Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.